Kane Biotech (TSE:KNE) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kane Biotech has seen a substantial revenue increase in the third quarter of 2024, primarily driven by the first commercial sale of its revyve™ Antimicrobial Wound Gel. The company also announced significant corporate developments, including new distribution agreements and regulatory approvals, positioning it well for future growth in the wound care market.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.